Alexandrosz Czira
Overview
Explore the profile of Alexandrosz Czira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
60
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang S, Czira A, Harley J, Rothnie K, Lee L, Small M
NPJ Prim Care Respir Med
. 2025 Feb;
35(1):10.
PMID: 40011538
Inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as maintenance-only or MART...
2.
Joksaite S, Wood R, Ismaila A, Camidge L, Mizukami A, Czira A, et al.
BMJ Open
. 2024 Dec;
14(12):e080864.
PMID: 39632104
Objectives: To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan....
3.
Rothnie K, Wood R, Czira A, Banks V, Camidge L, Massey O, et al.
BMJ Open Respir Res
. 2024 May;
11(1).
PMID: 38772900
Background: Compared with multiple-inhaler triple therapy (MITT), single-inhaler triple therapy (SITT) with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) demonstrated improved lung function and meaningful improvements in chronic obstructive pulmonary disease (COPD) Assessment Test...
4.
Beeh K, Rothnie K, Claussen J, Hardtstock F, Knapp R, Wilke T, et al.
Int J Chron Obstruct Pulmon Dis
. 2024 Apr;
19:945-956.
PMID: 38646606
Purpose: To assess patient characteristics of users and new initiators of triple therapy for chronic obstructive pulmonary disease (COPD) in Germany. Patients And Methods: Retrospective cohort study of patients with...
5.
Roberts M, Duh M, Rothnie K, Zhang S, Czira A, Slade D, et al.
Respir Med
. 2024 Apr;
226:107630.
PMID: 38593886
Introduction: Definitions of moderate asthma exacerbation have been inconsistent, making their economic burden difficult to assess. An algorithm to accurately identify moderate exacerbations from claims data is needed. Methods: A...
6.
Duh M, Roberts M, Rothnie K, Cheng W, Thompson-Leduc P, Zhang S, et al.
Respir Med
. 2024 Apr;
226:107629.
PMID: 38593885
Introduction: Despite adherence to inhaled corticosteroid/long-acting β-agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This...
7.
Ismaila A, Rothnie K, Wood R, Banks V, Camidge L, Czira A, et al.
Respir Res
. 2024 Apr;
25(1):152.
PMID: 38561735
No abstract available.
8.
Numbere B, Liu Y, Zhang S, Czira A, Lu Y
BMJ Open Respir Res
. 2024 Mar;
11(1).
PMID: 38448044
Introduction: For patients with asthma who remain symptomatic on medium-dose inhaled corticosteroid/long-acting β-agonist, add-on long-acting muscarinic antagonist is a treatment option, which can be administered as multiple-inhaler triple therapy (MITT)....
9.
Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R, et al.
BMJ Open
. 2024 Feb;
14(2):e072361.
PMID: 38326272
Objective: Management of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroid/long-acting β-agonist (ICS/LABA) improves lung function and health status and reduces COPD exacerbation risk versus monotherapy. This study described treatment...
10.
Czira A, Akiyama S, Ishii T, Wood R, Camidge L, Wallis H, et al.
Int J Chron Obstruct Pulmon Dis
. 2023 Dec;
18:2933-2953.
PMID: 38089540
Purpose: There is currently limited evidence for the optimal timing of triple therapy initiation in Japan, which is crucial for optimizing strategies for the effective treatment of chronic obstructive pulmonary...